Accelerating R&D (research and development) for rare disease in the UK
Genetic Alliance UK supported LifeArc to launch the Accelerating R&D (research and development) for rare disease in the UK report.
This report outlines clear, actionable recommendations to unlock the UK’s potential as a global leader in rare disease research and innovation, with the fundamental point: that when innovation happens here, people in the UK benefit first.
We collaborate with LifeArc in a few ways, supporting their rare disease translation research centres and we’re proud to have brought together our campaigning networks to deliver this work. This is part of a bigger piece of activity, bringing together our Patient Empowerment Group, the parliamentary groups on genetic, rare and undiagnosed conditions, all aimed at securing a next phase of the UK Rare Diseases Framework.
Nick Meade, CEO of Genetic Alliance UK, and Sam Barrell, CEO of LifeArc, presenting the Accelerating R&D for rare disease in the UK report.